Location of Repository

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses

By C Gridelli, L Frontini, F Perrone, C Gallo, M Gulisano, S Cigolari, F Castiglione, S F Robbiati, G Gasparini, G P Ianniello, A Farris, M C Locatelli, R Felletti and E Piazza

Abstract

Our aim was to study the activity and toxicity of the gemcitabine plus vinorelbine (Gem Vin) combination and to identify the optimal dose. Previously untreated patients aged < 70 years, with stage IV or IIIb (not candidates for radiotherapy) non-small cell lung cancer were eligible. Studied dose-levels of Gem Vin, administered on days 1 and 8 every 3 weeks, were (mg m–2): level I = 1000/25; level II = 1200/25; level III = 1000/30; level IV = 1200/30. A feasibility study was performed at each dose-level, followed by a single-stage phase II study. Dose-level IV was unfeasible because of grade 4 neutropenia. Overall, out of 126 patients enrolled in phase II studies, there were one complete and 32 partial responses (response rate 26%: 95% CI 18–34%). Response rates were 27.9%, 21.4% and 29.3% at levels I, II and III, respectively. The treatment was well tolerated. Toxicity was less frequent and severe at level I. Overall median survival was 33 weeks (95% CI 28–40). Descriptive quality of life analysis showed that patients with a worse baseline global health status score tended to drop out of the study earlier than those with a better score. Gem Vin is feasible at different doses. It is sufficiently active and well tolerated. A phase III study to compare the effect on quality of life of Gem Vin (level I) vs cisplatin-based chemotherapy is ongoing. © 2000 Cancer Research Campaig

Topics: Regular Article
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2363528
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (1993). for the EORTC Study Group on Quality of Life
    2. Rep 69: 1375–1381 APPENDIX Participating Authors and Institutions
    3. (1981). Reporting results of cancer treatment. Cancer 47: 207–214 Non Small Cell Lung Cancer Collaborative Group

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.